Intelligent Implants' SmartFuse gets FDA clearance for spinal fusions

Carly Behm -   Print  |

Intelligent Implants' remote orthopedics platform received breakthrough designation by the FDA for use in lumbar spinal fusion patients.

The platform, SmartFuse, is designed to remotely stimulate, control and monitor bone growth. The system's remote monitoring allows real-time clinical decision making.

FDA breakthrough designation speeds up the development, assessment and review for select devices.

"We look forward to working closely with the FDA through future clinical trials and review processes for SmartFuse," CEO John Zellmer said in a May 28 news release. "We expect to benefit from additional FDA input during premarket development as well during the submission process and through an expedited review once the submission is filed."

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers